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Monocytes play a key role in the inflammatory stage of the healing process. To allow monocyte migration to injured tissues, the
balances between secreted matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) must be finely modulated. However,
a reduction of blood supply and local oxygen tension can modify the phenotype of immune cells. Intriguingly, hypoxia might
be targeted by new effective oxygenating devices such as 2H,3H-decafluoropentane- (DFP-) based oxygen-loaded nanodroplets
(OLNs). Here, hypoxia effects on gelatinase/TIMP release fromhuman peripheralmonocytes were investigated, and the therapeutic
potential of dextran-shelled OLNs was evaluated. Normoxic monocytes constitutively released ∼500 ng/mL MMP-9, ∼1.3 ng/mL
TIMP-1, and ∼0.6 ng/mL TIMP-2 proteins. MMP-2 was not detected. After 24 hours, hypoxia significantly altered MMP-9/TIMP-1
balance by reducingMMP-9 and increasingTIMP-1, without affecting TIMP-2 secretion. InterestinglyOLNs, not displaying toxicity
to human monocytes after cell internalization, effectively counteracted hypoxia, restoring a normoxia-like MMP-9/TIMP-1 ratio.
The action of OLNswas specifically dependent on time-sustained oxygen diffusion up to 24 h from their DFP-based core.Therefore,
OLNs appear as innovative, nonconventional, cost-effective, and nontoxic therapeutic tools, to be potentially employed to restore
the physiological invasive phenotype of immune cells in hypoxia-associated inflammation.
1. Introduction
The innate immune system provides the first line of defense
against exogenous or endogenous danger signals, promoting
a protective inflammatory response that evolves through
different phases, from initiation and full inflammation to
resolution and reestablishment of tissue integrity. In this
perspective, inflammation has been described as an adaptive
response to tissue malfunction or homeostatic imbalance [1].
However, the inflammatory activities are potentially harmful
to the host; therefore, they need to be tightly controlled
to prevent excessive tissue damage [2]. Human monocytes,
constituting almost 10% of the total leukocytes, play a central
role in the different stages of the inflammatory response,
including antigen recognition and presentation, initiation of
the adaptive immune response, and regulation of healing
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processes [3]. This wide spectrum of activities requires
monocyte migration to the injured tissues and their fast
adaptation to the changing microenvironment.
To allow extravasation from the blood vessels and
migrate into the tissues, monocytes secrete several classes
of proteins, including matrix metalloproteinases (MMPs).
MMPs, a family of proteolytic enzymes secreted as latent
zymogens activated locally by other proteases and inhibited
by their secreted endogenous inhibitors (tissue inhibitor of
metalloproteinases (TIMPs)) can collectively process all the
components of the basementmembrane and the extracellular
matrix [4]. In addition, MMPs can cleave other molecules,
including cytokines, chemokines, growth factors, enzymes,
and membrane-bound proteins, thus promoting their activa-
tion, inhibition, degradation, or shedding and playing pivotal
roles during inflammation [5, 6].
On the other hand, hypoxia, which is functionally defined
as the inability of oxygen delivery to meet oxygen demands
of the tissue [7], has been demonstrated in a variety of acute
and chronic inflammatory sites, including chronic wounds,
sites of bacterial infection, myocardial infarcts, the synovium
in rheumatoid arthritis patients, and the arterial intima
in atherosclerotic lesions [8]. Depending on its duration
and severity, hypoxia can drive inflammation and aggravate
cellular and tissue injury by inducing monocyte recruitment
and causing their accumulation in hypoxic regions [9].
Hypoxia profoundly affects monocyte morphology, viability,
and functionality; even more so, it alters the expression of
surface molecules and release of soluble molecules, including
cytokines, MMPs, and TIMPs [10].
To counteract tissue hypoxia, in recent years intensive
research has been carried on to develop new oxygen carriers,
either based on hemoglobin, developed as cell-free suspen-
sions [11, 12] or on perfluorocarbons, carryingmolecular oxy-
gen without actually binding it, thus favoring gas exchange
[13]. Among the alternative options currently under investi-
gation, perfluoropentane-based oxygen-loaded nanobubbles
[14, 15] and 2H,3H-decafluoropentane- (DFP-) based nan-
odroplets [16, 17], both coated with biocompatible polysac-
charides such as chitosan or dextran, have been recently
reported to deliver both in vitro and in vivo clinically relevant
oxygen amounts, thus acting as efficient, biocompatible, and
stable oxygen delivery systems. In particular, the nanometer
size displays several advantages on a therapeutic level: (i) in
accordance with Laplace’s law, the smaller the bubble radius,
the higher the oxygen partial pressure; (ii) the carriers are
likely to pass through the nanosized interendothelial gaps
of fenestrated capillaries; (iii) when needed, oxygen release
can be easily promoted upon complementary ultrasound
administration [17].
In the present work, new dextran-shelled oxygen-loaded
nanodroplets (OLNs), which have recently been developed,
characterized, and patented by our group [17], were chal-
lenged for their ability to counteract hypoxia in human
monocytes isolated from peripheral blood, in order to assess
their potential suitability as therapeutics during inflamma-
tion. OLN cytotoxicity and cell viability, as well as cellular
uptake, were evaluated. Then, hypoxia and OLN effects on
the secretion of gelatinases (MMP-9 and MMP-2) and their
inhibitors (TIMP-1 and TIMP-2) by human monocytes were
analyzed.
2. Materials and Methods
2.1. Materials. All materials were from Sigma-Aldrich (St.
Louis, MO), aside from those listed below. Sterile plastics
were from Costar (Cambridge, UK); Panserin 601 monocyte
medium was from PAN Biotech (Aidenbach, Germany);
cell culture medium RPMI 1640, TRIzol, M-MLV, oligo-
dT, sense and anti-sense primers and Platinum Taq DNA
Polymerase were from Invitrogen (Carlsbad, CA); DNA-
free kit was from Ambion (Austin, TX); Beacon Designer
2.1 software was from Premier Biosoft International (Palo
Alto, CA); dNTPs were from Applied Biosystem (Foster
City, CA); ELISA kits for hMMP-9 (CAT# ELH-MMP9-
001), hTIMP-1 (CAT#ELH-TIMP1-001), andhTIMP-2 (CAT#
ELH-TIMP2-001) were from RayBiotech (Norcross, GA);
iCycler iQ Real Time Detection System Software version
3.0, electrophoresis reagents, and computerized densitometer
Geldoc were from Bio-rad Laboratories (Hercules, CA);
Synergy HT microplate reader was from Bio-Tek Instru-
ments (Winooski, VT); recombinant proMMP-9 and MMP-
9 were kindly gifted by Professor Ghislain Opdenakker and
Professor Philippe Van den Steen (Catholic University of
Leuven, Belgium); ethanol (96%) was obtained from Carlo
Erba (Milan, Italy); Epikuron 200 (soya phosphatidylcholine
95%) was fromDegussa (Hamburg, Germany); palmitic acid,
decafluoropentane (DFP), dextran sodium salt (100 kDa),
and polyvinylpyrrolidone (PVP) were from Fluka (Buchs,
Switzerland); ultrapure water was obtained using a 1-800
Millipore system (Molsheim, France); Ultra-Turrax SG215
homogenizer was from IKA (Staufen, Germany); Stratalinker
UV Crosslinker 1800 was from Stratagene (La Jolla, CA);
Delsa Nano C analyzer was from Beckman Coulter (Brea,
CA); Miniscope 100 EPR spectrometer was fromMagnettech
(Berlin, Germany); Philips CM10 instrument was from
Philips (Eindhoven, Netherlands); Formvar-coated copper
grid was from Polysciences Europe GmbH (Eppelheim, Ger-
many); XDS-3FL microscope was from Optika (Ponteranica,
Italy); polarizing microscope was from Spencer Lens Com-
pany (Buffalo, NY); Discovery HR1 Hybrid Rheometer was
from TA instruments (Milan, Italy).
2.2. Preparation of Dextran-Shelled OLN and Control Solu-
tions. OLNs, oxygen-free nanodroplets (OFNs), and oxy-
gen-saturated solution (OSS) were prepared as previously
described [17]. Briefly, 1.5mL DFP, 0.5mL polyvinylpyrroli-
done, and 1.8mL Epikuron 200 (solved in 1%w/v ethanol and
0.3%w/v palmitic acid solution) were homogenized in 30mL
phosphate-buffered saline (PBS) solution (pH 7.4) for 2min
at 24000 rpm by using Ultra-Turrax SG215 homogenizer. For
OLNs, the solution was saturated with O
2
for 2min. Finally,
1.5mL dextran or rhodamine B-labeled dextran solution was
added drop-wise whilst the mixture was homogenized at
13000 rpm for 2min. For OFN and OSS PBS formulations,
OLN preparation protocol was applied omitting O
2
or dex-
tran/DFP addition, respectively. After manufacturing, OLNs,
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OFNs, and OSS were sterilized through UV-C exposure
for 20min. Thereafter, UV-C-treated materials were incu-
bated with cell culture RPMI 1640 medium in a humidified
CO
2
/air-incubator at 37∘C up to 72 h, not displaying any
signs of microbial contamination when checked by optical
microscopy. Moreover, UV-C-sterilized O
2
-containing solu-
tions underwent further analyses through O
3
measurement
and electron paramagnetic resonance (EPR) spectroscopy,
showingnoO
3
generation andnegligible singlet oxygen levels
immediately after UV-C exposure.
2.3. Characterization of Dextran-Shelled OLN and Control
Solutions. Themorphology of nanodroplet formulations was
determined by transmitting electron microscopy (TEM) and
by optical microscopy. TEM analysis was carried out using
a Philips CM10 instrument, whereas optical microscopy was
carried out using a XDS-3FL microscope. For TEM analysis
nanodroplet formulations were dropped onto a Formvar-
coated copper grid and air-dried before observation. Further-
more, average diameters and shell thickness were elaborated
from TEM images. Sizes, polydispersity indexes, and zeta
potentials of nanodroplets were determined by dynamic
light scattering using Delsa Nano C instrument, displaying
a (0.6 nm–7𝜇m) range for measurements of particle size
distribution. The polydispersity index indicates the size dis-
tribution within a nanodroplet population. For zeta poten-
tial determination, formulation samples were placed into
an electrophoretic cell, where an electric field of approxi-
mately 30V/cm was applied. The electrophoretic mobility
was converted into zeta potential using the Smoluchowski
equation [18]. The refractive indexes of OLN and OFN for-
mulations were calculated through a polarizing microscope.
The viscosity and the shell shear modulus were determined
through a Discovery HR1 Hybrid Rheometer. Immediately
after preparation, oxygen content of OLNs and OSS was
evaluated for characterization purposes by adding known
amounts of sodium sulfite and measuring generated sodium
sulfate, according to the reaction:
2Na
2
SO
3
+O
2
→ 2Na
2
SO
4 (1)
The stability of formulations stored at 4∘C, 25∘C, or 37∘C
was evaluated over time up to 6 months by determining
morphology, sizes, and zeta potential of nanodroplets by
optical microscopy and light scattering.
2.4. Preparation and Handling of Monocytes. Human mono-
cytes were separated by Ficoll centrifugation [19] from freshly
collected buffy coats discarded from blood donations by
healthy adult donors of both sexes provided by the local
blood bank (AVIS, Associazione Volontari Italiani Sangue,
Torino, Italy). Separated lymphocytes and monocytes were
resuspended in RPMI medium and plated on six-well plates.
Each well received 8 × 106 cells.The plates were incubated in a
humidified CO
2
/air-incubator at 37∘C for 60min.Thereafter,
nonadherent cells were removed by three washes with RPMI
and remaining adherent cells (∼1 × 106 monocytes/well) were
incubated overnight at 37∘C.The day after, wells were washed
with RPMI and Panserin 601 monocyte medium was added
(2mL/well). Before starting experiments, a preselection of
cell populations was taken as a precautionary measure to
reduce variability among donors, as previously described
[20]. Briefly, cell cultures isolated through Ficoll separation
were analyzed by flow cytometry. Only cell populations
showing at least 70% monocytes were used for following
experiments. Additionally, in order to avoid the use of NF-
𝜅B preactivated monocytes, cells were analyzed by Real
Time RT-PCR. in each cell preparation a cell aliquot was
stimulated or not with LPS (1𝜇g/mL) for 4 h, and TNF-
𝛼 RNA production measured in lysates by Real Time RT-
PCR. Total cellular RNA was isolated from monocytes by
TRIzol, according to the manufacturer’s instructions, and
eluted in 20 𝜇L of diethyl pyrocarbonate water. To remove any
contaminating DNA, RNA was treated with Ambion’s DNA-
free kit. Subsequently, 6 𝜇g of RNA was reverse transcribed
into single-stranded cDNA using Moloney murine leukemia
virus reverse transcriptase (200U/𝜇L final concentration)
and oligo(dT) (25 𝜇g/𝜇L final concentration). Real Time RT-
PCR analysis was performed with iCycler iQ real-time RT-
PCR Detection System apparatus and Chemidoc software,
version 3.0 (Bio-Rad). A housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used. Primer
sequences were from the Bio-Rad library: forward, 5󸀠-GAA
GGT GAA GGT CGG AGT-3󸀠 and reverse, 5󸀠-CAT GGG
TGG AAT CAT ATT GGA A-3󸀠. For each 25-𝜇L PCR mix:
1 𝜇L of cDNA (corresponding to 105 cells); 1.0𝜇L of sense
primer (10 𝜇M); 1.0 𝜇L of antisense primer (10 𝜇M); 0.5 𝜇L of
dNTP (10 mM); 1.5 𝜇L of MgCl
2
(50mM); 1.25U of Platinum
TaqDNA Polymerase; 2.5 𝜇L of buffer (10X); 1.7 𝜇L of SYBR
Green (stock 1 : 10,000); and 14.55 𝜇L of PCR-grade water
were mixed together. DNA polymerase was preactivated for
2min at 94∘C, and the amplification was performed by 50
cycles (TNF) or 35 cycles (GAPDH) with denaturation at
94∘C for 30 s, annealing at 60∘C for 30 s and extension at
72∘C for 30 s. Relative quantitation for TNF, expressed as fold
variation over untreated control cells, was calculated after
determination of the difference between CT of the given gene
A (TNF) and that of the calibrator gene B (GAPDH) using the
2
−ΔΔCT method. Only unstimulated monocyte populations
(NF-𝜅B-nonactivated cells) showing at least a gap of three
PCR cycles of cDNAamplification between controls and LPS-
stimulated cells were used for the subsequent experiments.
2.5. Evaluation of OLNUptake byHumanMonocytes. Human
monocytes were plated in 24-well plates on glass cov-
erslips and incubated in Panserin 601 medium for 24 h
with/without 200𝜇L rhodamine B-labeled OLNs in a humid-
ified CO
2
/air-incubator at 37∘C. After 4󸀠,6-diamidino-2-
phenylindole (DAPI) staining to visualize cells nuclei, fluo-
rescence imageswere acquired by a LSM710 inverted confocal
laser scanning microscope equipped with a Plan-Neofluar
63 × 1.4 oil objective that allowed a field view of at least 5
cells. Wavelength of 544 nm was used to detect OLNs and of
460 nm to detect the labeled nuclei. The acquisition time was
400ms.
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2.6. OLN Cytotoxicity Studies. The potential cytotoxic effects
of OLN and control formulations were measured as the
release of lactate dehydrogenase (LDH) from human adher-
ent monocytes into the extracellular medium as previously
described [21]. Briefly, cells were incubated in Panserin 601
medium for 24 h in the presence or absence of increasing
doses (100–400 𝜇L) ofOLNs or 200𝜇L ofOFNs orOSS, either
in normoxic (20% O
2
) or in hypoxic (1% O
2
) conditions,
in a humidified CO
2
/air-incubator at 37∘C. Then, 1mL of
cell supernatants was collected and centrifuged at 13000 g for
2min. Cells were washed with fresh medium, detached with
trypsin/EDTA (0.05/0.02% v/v), washed with PBS, resus-
pended in 1mL of TRAP (82.3mM triethanolamine, pH 7.6),
and sonicated on ice with a 10 s burst. 5 𝜇L of cell lysates
and 50 𝜇L of cell supernatants were diluted with TRAP and
supplemented with 0.5mM sodium pyruvate and 0.25mM
NADH (300 𝜇L as a final volume) to start the reaction. The
reaction was followed measuring the absorbance at 340 nm
(37∘C) with Synergy HT microplate reader. Both intracel-
lular and extracellular enzyme activities were expressed as
𝜇mol of oxidized NADH/min/well. Finally, cytotoxicity was
calculated as the net ratio between extracellular and total
(intracellular + extracellular) LDH activities.
2.7. Cell Viability Studies. Cell viability was evaluated using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Human adherent monocytes were incubated in
Panserin 601 medium for 24 h with/without increasing doses
(100–400 𝜇L) of OLNs or 200𝜇L of OFNs or OSS, either
in normoxic (20% O
2
) or hypoxic (1% O
2
) conditions, in
a humidified CO
2
/air-incubator at 37∘C. Thereafter, 20𝜇L
of 5mg/mL MTT in PBS were added to cells for 3 addi-
tional hours at 37∘C. The plates were then centrifuged, the
supernatants discarded and the dark blue formazan crystals
dissolved using 100 𝜇L of lysis buffer containing 20% (w/v)
sodium dodecyl sulfate (SDS), 40%N,N-dimethylformamide
(pH 4.7 in 80% acetic acid). The plates were then read on
Synergy HTmicroplate reader at a test wavelength of 550 nm
and at a reference wavelength of 650 nm.
2.8. Measurement of the Levels of Latent and Active Forms
of MMP-9 Protein in Cell Supernatants. The levels of latent
and active forms ofMMP-9 were evaluated by gelatin zymog-
raphy in the cell supernatants as previously described [22].
Briefly, human adherent monocytes (1 × 106 cells/well) were
incubated in Panserin 601 medium for 24 h with/without
200𝜇L of OLNs, OFNs, or OSS, either in normoxic (20%
O
2
) or hypoxic (1% O
2
) conditions, in a humidified CO
2
/air-
incubator at 37∘C. Thereafter, 15𝜇L cell supernatants/lane
were loaded on 8% polyacrylamide gels containing 0.1%
gelatin under nondenaturing and nonreducing conditions.
Following electrophoresis, gels were washed at room temper-
ature for 2 h in milliQ water containing 2.5% (v/v) Triton-
X100 and incubated for 18 h at 37∘C in a collagenase
buffer containing (mM): NaCl, 200; Tris, 50; CaCl
2
, 10; and
0.018% (v/v) Brij 35, pH 7.5, with or without 5mM EDTA
to exclude nonspecific bands. At the end of the incubation,
the gels were stained for 15min with Coomassie blue (0.5%
Coomassie blue in methanol/acetic acid/water at a ratio
of 30 : 10 : 60). The gels were destained in milliQ water.
Densitometric analysis of the bands, reflecting the total levels
of latent and active forms of MMP-9, was performed using a
computerized densitometer.
2.9. Measurement of MMP-9, TIMP-1, and TIMP-2 Produc-
tion. Human adherent monocytes (1 × 106 cells/well) were
incubated in Panserin 601 medium for 24 h with/without
200𝜇L of OLNs, OFNs, or OSS, either in normoxic (20%
O
2
) or hypoxic (1% O
2
) conditions, in a humidified CO
2
/air-
incubator at 37∘C. Thereafter, cell supernatants were col-
lected, and the levels of MMP-9, TIMP-1, and TIMP-2 were
assayed in 100 𝜇L of monocyte supernatants by specific
ELISA. Standard calibration curves were generated with
rhMMP-9, rhTIMP-1, and rhTIMP-2, according to the man-
ufacturer’s instructions.
2.10. Statistical Analysis. For each set of experiments, data
are shown as means + SEM (LDH, MTT, densitometry, and
ELISA results) or as a representative image (confocal micros-
copy and gelatin zymography results) of three independent
experiments with similar results. SEMwas used since biolog-
ical data were considered as inferential information (see [23]
for an exhaustive review). All data were analyzed by a one-
way analysis of variance (ANOVA) followed by Tukey’s post
hoc test (software: SPSS 16.0 forWindows, SPSS Inc., Chicago,
IL).
3. Results
3.1. Characterization of OLND and Control Formulations.
Before being employed in the subsequent experiments, all
OLND preparations were characterized for morphology
and shell thickness, by optical and transmitting electron
microscopy (TEM); size, particle size distribution, polydis-
persity index and zeta potential, by dynamic light scattering;
refractive index by polarizing microscopy; viscosity and shell
shearmodulus by rheometry; and oxygen content (before and
after UV-C sterilization) through a chemical assay. Results
were always in line with literature data [17]. Both OLNs
and OFNs displayed spherical shapes. All sizes were in
the nanometer range, with average diameters ranging from
∼240 nm for OFNs to ∼590 nm for OLNs. Zeta potentials
were ∼−25mV. Refractive indexes were similar for both OLN
and OFN formulations (∼1.33). OLN formulation displayed
a viscosity value of 1.59188 𝑒 − 3Pa⋅s and a shear modulus
value of 5.43 𝑒 − 2mPa, calculated at a shear rate value of
150 s−1. OLNs displayed a good oxygen-storing capacity of
about 0.40mg/mL of oxygen before and after 20min UV-C
sterilization. Such oxygen amount was comparable with that
of OSS.
3.2. OLN Effects on Human Monocyte Viability. OLN tox-
icity was evaluated by testing in vitro cultures of human
adherent monocytes isolated from peripheral blood. As
shown in Figure 1 (Figure 1(a): LDHassay; Figure 1(b): MTT
assay), increasing volumes of OLN PBS suspensions (5, 10,
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Figure 1: Hypoxia and OLN effects on human monocyte viability. Human adherent monocytes (106 cells/2mL Panserin 601 medium) were
left untreated or treated with increasing doses (100–400 𝜇L) of OLNs or with 200 𝜇L OFNs or OSS for 24 h in normoxia (20% O
2
, black
columns/squared-lines) or hypoxia (1% O
2
, white columns/squared-lines). After collection of cell supernatants and lysates, cytotoxicity
percentage wasmeasured through LDH assay (panels (a) and (c)), whereas cell viability percentage wasmeasured throughMTT assay (panels
(b) and (d)). Results are shown as means + SEM from three independent experiments. Data were also evaluated for significance by ANOVA.
No significant differences between normoxic and hypoxic control cells or betweenOLN-treated and untreated cells were observed (all panels).
and 20% v/v) were not toxic to monocytes (106 cells per
2mL Panserin 601 cell culture medium) both in normoxic
(20% O
2
) and hypoxic (1% O
2
) conditions. Therefore, the
intermediate OLN dosage (10% v/v) was chosen to perform
the subsequent experiments. Toxicity of 10% v/v OFNs and
OSS (controls) was also assayed (Figure 1(c): LDH assay;
Figure 1(d): MTT assay), not showing any effect on viability
of treated cells with respect to untreated cells. As expected,
0.5% Triton X-100, an effective cytotoxic agent employed as
positive control, induced 100% cell death (not shown).
3.3. OLN Internalization by Human Monocytes. To check
whether OLNs were uptaken by human adherent mono-
cytes isolated from peripheral blood, a confocal microscopy
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Figure 2: OLN internalization by human monocytes. Human adherent monocytes (106 cells/2mL Panserin 601 medium) were left untreated
(a) or treated with 200𝜇L rhodamine B-labeled dextran-shelled OLNs (b) for 24 h in normoxia (20% O
2
). After DAPI staining, cells were
checked by confocal microscopy. Results are shown as representative images from three independent experiments. Left panels: cell nuclei
after DAPI staining (blue). Central panels: rhodamine B-labeled dextran-shelled OLNs (red). Right panels: merged images. Magnification:
63x.
approach was chosen. Human adherent monocytes (106 cells
per 2mL Panderin 601 cell culture medium) were incubated
with 10% v/v rhodamine B-labeled dextran-shelled OLN PBS
suspensions for 24 h in normoxic conditions. As shown in
Figure 2, OLNs were internalized by human monocytes.
3.4. Hypoxia and OLN Effects on MMP-9 Secretion by Human
Monocytes. After incubating for 24 h human adherentmono-
cytes isolated from peripheral blood (106 cells per 2mL cell
culture medium) with or without 10% v/v OLNs, OFN, or
OSS, both in normoxic (20%O
2
) and hypoxic (1%O
2
) condi-
tions, MMP-9 secretion into cell supernatants was evaluated.
Results are shown in Figure 3. ELISA analysis (Figure 3(a))
displayed that normoxic untreated monocytes constitutively
secreted ∼500000 pg/mL MMP-9. Complementary inves-
tigation by gelatin zymography (Figure 3(b)) and subse-
quent densitometry (Figures 3(c) and 3(d)) revealed that
both latent and activated forms of MMP-9 were released
by normoxic monocytes. Furthermore, hypoxia was shown
through both analyses to significantly alterMMP-9 secretion,
lowering the 92 kDa proMMP-9 protein levels and fully
inhibiting the release of the 83 kDa activated form. OLNs—
but notOFNs andOSS—fully reversed hypoxia effects, restor-
ing normoxic proMMP-9 and MMP-9 secretion. Notably,
neither gelatin zymography nor ELISA analyses detected any
MMP-2 protein amounts in monocyte supernatants.
3.5. Hypoxia and OLN Effects on TIMP Secretion by Human
Monocytes and MMP-9/TIMP-1 Balances. Human adherent
monocytes (106 cells per 2mL cell culture medium) were
incubated for 24 h with or without 10% v/v OLNs, OFN,
or OSS, both in normoxic (20% O
2
) and hypoxic (1% O
2
)
conditions. Thereafter, the secretion of TIMP-1 and TIMP-2
was evaluated by ELISA. As shown in Figure 4, normoxic
untreated monocytes constitutively released ∼1300 pg/mL
TIMP-1 and ∼600 pg/mL TIMP-2. Hypoxia significantly
increased by almost 45% the secreted levels of TIMP-1 while
did not affect TIMP-2 production. OLNs—but not OFNs
and OSS—effectively abrogated hypoxia effects, restoring
physiological TIMP-1 amounts also in hypoxic culturing
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Figure 3: Hypoxia and OLN effects on MMP-9 secretion by human monocytes. Human adherent monocytes (106 cells/2mL Panserin 601
medium) were left untreated or treated with 200𝜇L OLNs, OFNs, or OSS for 24 h in normoxia (20% O
2
; panels (a), (c), and (d): black
columns; panel (b): odd lanes) or hypoxia (1% O
2
; panels (a), (c), and (d): white columns; panel (b): even lanes). After collection of cell
supernatants, MMP-9 protein levels were quantified by ELISA (panel (a)), whereas MMP-9 latent/active forms were analyzed by gelatin
zymography (panel (b)) and subsequent densitometry (panels (c)-(d)). For gelatin zymography, recombinant human MMP-9 (83 kDa) was
employed as a standard marker (st). Results are shown as means + SEM (panels (a), (c)-(d)) or as a representative gel (panel (b)) from three
independent experiments. ELISA and densitometric data were also evaluated for significance by ANOVA: ∗ versus normoxic control cells:
𝑃 < 0.0001 (panel (a)), 𝑃 < 0.02 (panel (c)), and 𝑃 < 0.0001 (panel (d)); ∘ versus hypoxic control cells: 𝑃 < 0.0001 (panel (b)), 𝑃 < 0.005
(panel (c)), and 𝑃 < 0.0001 (panel (d)).
conditions. Consequently, the balance between MMP-9 and
its inhibitor was calculated. As shown in Figure 5, hypoxia
significantly affected MMP-9/TIMP-1 stoichiometric ratio,
which was reduced by ∼50% with respect to cells cultured
in normoxic conditions. OLNs—but not OFNs and OSS—
effectively counteracted hypoxia effects, restoring the phys-
iological MMP-9/TIMP-1 ratio to a value similar to that
observed in normoxia.
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Figure 4: Hypoxia and OLN effects on protein levels of gelatinase inhibitors (TIMP-1 and TIMP-2) secreted by human monocytes. Human
adherent monocytes (106 cells/2mL Panserin 601 medium) were left untreated or treated with 200 𝜇L OLNs, OFNs, or OSS for 24 h in
normoxia (20%O
2
; black columns, both panels) or hypoxia (1%O
2
; white columns, both panels). After collection of cell supernatants, TIMP-
1 (panel (a)) and TIMP-2 (panel (b)), protein levels were quantified by ELISA. Results are shown as means + SEM from three independent
experiments. Data were also evaluated for significance by ANOVA: ∗ versus normoxic control cells: 𝑃 < 0.02 (panel (a)) and 𝑃 not significant
(panel (b)); ∘ versus hypoxic control cells: 𝑃 < 0.02 (panel (a)) and 𝑃 not significant (panel (b)).
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Figure 5: Hypoxia and OLN effects on MMP-9/TIMP-1 balances
upon secretion by humanmonocytes. MMP-9/TIMP-1 stoichiomet-
ric ratio was calculated after results from ELISA investigation (see
Figures 3 and 4). Results are shown as means + SEM from three
independent experiments. Data were also evaluated for significance
by ANOVA: ∗ versus normoxic control cells: 𝑃 < 0.0001; ∘ versus
hypoxic control cells: 𝑃 < 0.0001.
4. Discussion
The present study investigated the in vitro effects of hypoxia
on the secretion of gelatinases and their inhibitors by
human adherent monocytes isolated from peripheral blood
and explored the therapeutic potential of innovative and
nonconventional dextran-shelled and DFP-cored OLNs to
counteract hypoxia-dependent dysregulation of the release of
these molecules.
Human monocytes were cultured in normoxic condi-
tions or exposed to controlled hypoxia. Normoxic mono-
cytes constitutively released both latent and active forms of
MMP-9 (but not MMP-2), as well as TIMP-1 and TIMP-
2, in line with previous reports on human monocytes [24–
27]. Hypoxia strongly impaired MMP-9/TIMP-1 balance by
reducing MMP-9 secretion and increasing TIMP-1 release.
Notably, hypoxic monocytes did not undergo apoptosis or
necrosis during the observational period, in accordance with
data from previous studies [28]. Therefore, the reduced
proMMP-9 and MMP-9 levels in cell supernatants were not
caused by a decreased number of cells but appeared as a direct
consequence of monocyte adaptation to the hypoxic stress.
Interestingly, it has been previously reported that in human
monocytes prolonged hypoxia leads to the accumulation of
intracellular proMMP-9 via cytoskeletal-mediated inhibition
of its trafficking, thus reducing its secreted levels [28]. Lahat
and colleagues have also reported that hypoxia reduces
by three- to four-fold the TIMP-2 secretion from human
primary monocytes as well as U937 and THP-1 monocyte
cell lines, by inhibiting TIMP-2 transcription via mech-
anisms involving SP-1 transcription factor [29]. However,
in our experiments, hypoxia did not affect TIMP-2 levels
in monocyte supernatants. The discrepancy between the
present results and those obtained by Lahat’s group appears as
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a likely consequence of the different duration of monocyte
incubation in hypoxic conditions in either study (24 h versus
72 h).
Once we determined the entity of hypoxia-dependent
dysregulation of secretedMMP-9/TIMP-1 balances in human
adherentmonocytes, OLNswere challenged as potential tools
to counteract hypoxia effects. These innovative and noncon-
ventional gas nanocarriers, recently developed by our group
[16, 17], display a core structure based on DFP, a liquid fluo-
rocarbon which can carry molecular oxygen without actually
binding it and favors gas exchange [30]. Fluorocarbons such
as DFP are extremely stable, biologically inert, and rapidly
excreted into the expired air in a nonmetabolized form
after injection into the bloodstream, as emerged from the
available studies on their toxicity, absorption, distribution,
and excretion [31, 32]. On the other hand, dextran represents
the main constituent of nanodroplet shells. Toxicological
studies showed that dextran, along with the products of its
mechanochemical processing, can be classified as class 4
(low-toxicity) substance [33]. Dextran-based hydrogels are
currently used as matrices in tissue engineering, without
showing signs of inflammation in vivo [11, 34, 35].
Before being employed in biological experiments, all
dextran-shelled/DFP-cored nanodroplet preparations were
meticulously characterized for morphology, average diam-
eters, size distribution, polydispersity index, zeta potential,
refractive index, viscosity, shell shear modulus, and oxygen
content (both before and after UV-C sterilization). For all
these parameters, results were consistent with those pre-
viously obtained and recently published [17]: nanodroplets
displayed spherical shapes, nanometric sizes, and negative
charges, as well as similar viscosity and shell shear modulus.
Nanodroplet formulations also proved to be physically stable
for the steric repulsion of the polymer chains, as assessed
by repeated measurements of their sizes and zeta potential
by dynamic light scattering over time up to 6 months. As
expected, OLN solutions also displayed a good oxygen-
storing capacity (0.4mgO
2
/mL) either before or after UV-C
sterilization, a procedure that was not accompanied by ozone
and singlet oxygen generation.
In the present work, human monocytes were incubated
in normoxic and hypoxic conditions with OLN and control
(OFN andOSS) preparations for 24 h. OLNs were uptaken by
humanmonocytes, not displaying any cytotoxic effects, either
in normoxia or hypoxia. Intriguingly, OLNs fully abrogated
hypoxia-dependent dysregulating effects on MMP-9 and
TIMP-1 secretion. Even in hypoxic culturing conditions,
OLN-treated monocytes secreted normoxia-like levels of
MMP-9, TIMP-1, and TIMP-2, and the physiological balance
between MMP-9 and TIMP-1 was restored.
Apparently, such an effect was specifically dependent on
time-sustained oxygen release from the DFP-based inner
core of OLNs, since it was not reproduced after treatment
with OFNs and OSS. These observations are in line with
previous data obtained from investigation on the dynamics of
oxygen release fromOLNs,OFNs, andOSS. Indeed,OLNs are
reportedly able to release significant and clinically relevant
amounts of oxygen into hypoxic environments in a time-
sustained manner, opposite to OSS, which releases oxygen
only transiently, and to OFNs, not releasing oxygen at all [16,
17]. In particular, 10% v/v OLNs, OFNs, and OSS have been
comparatively challenged for their ability to release oxygen
into Panserin 601 cell culturing medium and monitored by
oxymetry for 24 h. Although both OLNs and OSS induced
an immediate peak in oxygen release, only OLNs released
high oxygen amounts in a time-sustained manner for all the
observational 24 h-period, whereas OSS effect quickly van-
ished after a few hours and OFNs did not release significant
amounts of oxygen [36]. These data appear encouraging,
since they suggest that a topical administration of multiple
doses (e.g., twice a day) of OLNs might be effective. Nev-
ertheless, further preclinical and clinical studies on OLN
potential as therapeutic tools to target specific ischemic areas
are certainly needed. Intriguingly, OLNs can be further func-
tionalized after conjugation with specific antibodies to the
outer polysaccharidic shell [16, 17]. Furthermore, in a recent
work, OLNs have also been shown to counteract in vitro the
effects of hypoxia on the secretion of gelatinases and TIMPs
by human keratinocytes [36]. Since both monocytes and
keratinocytes play crucial roles throughout the overlapping
phases of wound healing (hemostasis, inflammation, cellular
proliferation, and remodeling) [37], this evidence supports
the hypothesis that OLNs could be hopefully employed to
promote tissue repair and regeneration in hypoxic chronic
wounds.
5. Conclusions
The present work shows that the balance between MMP-9
and TIMP-1 in human adherent monocytes is dramatically
altered by hypoxia. Intriguingly, dextran-shelled/DFP-cored
OLNs—a new platform of oxygen nanocarriers recently
developed by our group—are effective in counteracting the
effects of hypoxia, restoring normoxia-like MMP-9 and
TIMP-1 levels. These results, combined with the intrinsic
benefits of nanodroplets (size, charge, stability, controlled
release, and suitability for further drug functionalization,
drug loading, or encapsulation), support the proposal that
OLNs may serve as innovative, nonconventional, cost-effect-
ive, and nontoxic therapeutic tools to be potentially employed
for restoring the physiological invasive phenotype of immune
cells in hypoxia-associated inflammation. Based on the
present in vitro evidence, future preclinical studies to trans-
late this technology to clinical practice are encouraged.
Conflict of Interests
The authors declare that they have no conflict of interests.
Authors’ Contribution
Caterina Guiot and Mauro Prato equally contributed to the
work.
Acknowledgments
The authors gratefully acknowledge Compagnia di San Paolo
(Ateneo-San Paolo 2011 ORTO11CE8R grant to Caterina
10 Mediators of Inflammation
Guiot and Mauro Prato) and Universita` di Torino (ex-60%
2013 intramural funds to Caterina Guiot and Mauro Prato)
for funding support to this work. Mauro Prato holds a
professorship granted by Universita` degli Studi di Torino
and Azienda Sanitaria Locale-19 (ASL-19). Thanks are due
to Adriano Troia for suggestions on nanodroplet manufac-
turing, to Ghislain Opdenakker and Philippe Van den Steen
for kindly giving recombinant humanMMP-9, and toAssoci-
azione Volontari Italiani Sangue (AVIS Torino) for providing
fresh blood.
References
[1] R.Medzhitov, “Origin and physiological roles of inflammation,”
Nature, vol. 454, no. 7203, pp. 428–435, 2008.
[2] C. Nathan, “Points of control in inflammation,”Nature, vol. 420,
no. 6917, pp. 846–852, 2002.
[3] P. Italiani and D. Boraschi, “Frommonocytes to M1/M2macro-
phages: phenotypical vs. functional differentiation,” Frontiers in
Immunology, vol. 5, article 514, 2014.
[4] R. E. Vandenbroucke and C. Libert, “Is there new hope for ther-
apeutic matrix metalloproteinase inhibition?” Nature Reviews
Drug Discovery, vol. 13, no. 12, pp. 904–927, 2014.
[5] B. Cauwe, P. E. Van den Steen, and G. Opdenakker, “The
biochemical, biological, and pathological kaleidoscope of cell
surface substrates processed by matrix metalloproteinases,”
Critical Reviews in Biochemistry and Molecular Biology, vol. 42,
no. 3, pp. 113–185, 2007.
[6] A. Dufour and C. M. Overall, “Missing the target: Matrix met-
alloproteinase antitargets in inflammation and cancer,” Trends
in Pharmacological Sciences, vol. 34, no. 4, pp. 233–242, 2013.
[7] I. Papandreou, A. Powell, A. L. Lim, and N. Denko, “Cellular
reaction to hypoxia: sensing and responding to an adverse
environment,”Mutation Research—Fundamental andMolecular
Mechanisms of Mutagenesis, vol. 569, no. 1-2, pp. 87–100, 2005.
[8] C. Murdoch, M. Muthana, and C. E. Lewis, “Hypoxia regu-
lates macrophage functions in inflammation,” The Journal of
Immunology, vol. 175, no. 10, pp. 6257–6263, 2005.
[9] C. Murdoch, A. Giannoudis, and C. E. Lewis, “Mechanisms
regulating the recruitment of macrophages into hypoxic areas
of tumors and other ischemic tissues,” Blood, vol. 104, no. 8, pp.
2224–2234, 2004.
[10] J. S. Lewis, J. A. Lee, J. C. E. Underwood, A. L. Harris, and C. E.
Lewis, “Macrophage responses to hypoxia: Relevance to disease
mechanisms,” Journal of Leukocyte Biology, vol. 66, no. 6, pp.
889–900, 1999.
[11] P. Cabrales and M. Intaglietta, “Blood substitutes: evolution
from noncarrying to oxygen- and gas-carrying fluids,” ASAIO
Journal, vol. 59, no. 4, pp. 337–354, 2013.
[12] C. L. Modery-Pawlowski, L. L. Tian, V. Pan, and A. Sen Gupta,
“Synthetic approaches to RBC mimicry and oxygen carrier
systems,” Biomacromolecules, vol. 14, no. 4, pp. 939–948, 2013.
[13] C. I. Castro and J. C. Briceno, “Perfluorocarbon-based oxygen
carriers: review of products and trials,”Artificial Organs, vol. 34,
no. 8, pp. 622–634, 2010.
[14] R. Cavalli, A. Bisazza, A. Rolfo et al., “Ultrasound-mediated
oxygen delivery from chitosan nanobubbles,” International
Journal of Pharmaceutics, vol. 378, no. 1-2, pp. 215–217, 2009.
[15] R. Cavalli, A. Bisazza, P. Giustetto et al., “Preparation and char-
acterization of dextran nanobubbles for oxygen delivery,” Inter-
national Journal of Pharmaceutics, vol. 381, no. 2, pp. 160–165,
2009.
[16] C. Magnetto, M. Prato, A. Khadjavi et al., “Ultrasound-acti-
vated decafluoropentane-cored and chitosan-shelled nanod-
roplets for oxygen delivery to hypoxic cutaneous tissues,” RSC
Advances, vol. 4, no. 72, pp. 38433–38441, 2014.
[17] M. Prato, C.Magnetto, J. Jose et al., “2H,3H-decafluoropentane-
based nanodroplets: new perspectives for oxygen delivery to
hypoxic cutaneous tissues,” PLoS ONE, vol. 10, no. 3, Article ID
e0119769, 2015.
[18] A. Sze, D. Erickson, L. Ren, and D. Li, “Zeta-potential mea-
surement using the Smoluchowski equation and the slope of
the current-time relationship in electroosmotic flow,” Journal of
Colloid and Interface Science, vol. 261, no. 2, pp. 402–410, 2003.
[19] M. Polimeni, E. Valente, E. Aldieri, A. Khadjavi, G. Giribaldi,
and M. Prato, “Role of 15-hydroxyeicosatetraenoic acid in
hemozoin-induced lysozyme release from human adherent
monocytes,” BioFactors, vol. 39, no. 3, pp. 304–314, 2013.
[20] M. Polimeni, E. Valente, E. Aldieri, A. Khadjavi, G. Giribaldi,
and M. Prato, “Haemozoin induces early cytokine-mediated
lysozyme release from human monocytes through p38 MAPK-
andNF-kappaB- dependentmechanisms,” PLoSONE, vol. 7, no.
6, Article ID e39497, 2012.
[21] M. Polimeni, E. Valente, D. Ulliers et al., “Natural haemozoin
induces expression and release of human monocyte tissue
inhibitor of metalloproteinase-1,” PLoS ONE, vol. 8, no. 8,
Article ID e71468, 2013.
[22] A. Khadjavi, E. Valente, G. Giribaldi, and M. Prato, “Involve-
ment of p38MAPK in haemozoin-dependentMMP-9 enhance-
ment in human monocytes,” Cell Biochemistry and Function,
vol. 32, no. 1, pp. 5–15, 2014.
[23] G. Cumming, F. Fidler, and D. L. Vaux, “Error bars in experi-
mental biology,” The Journal of Cell Biology, vol. 177, no. 1, pp.
7–11, 2007.
[24] Y. Zhang, K. McCluskey, K. Fujii, and L. M. Wahl, “Differential
regulation of monocyte matrix metalloproteinase and TIMP-1
production by TNF-alpha, granulocyte-macrophage CSF, and
IL-1beta through prostaglandin-dependent and -independent
mechanisms,” Journal of Immunology, vol. 161, no. 6, pp. 3071–
3076, 1998.
[25] A. Bar-Or, R. K. Nuttall, M. Duddy et al., “Analyses of all matrix
metalloproteinase members in leukocytes emphasize mono-
cytes as major inflammatory mediators in multiple sclerosis,”
Brain, vol. 126, no. 12, pp. 2738–2749, 2003.
[26] T. Ichiyama, M. Kajimoto, M. Hasegawa, K. Hashimoto, T.
Matsubara, and S. Furukawa, “Cysteinyl leukotrienes enhance
tumour necrosis factor-𝛼-induced matrix metalloproteinase-9
in human monocytes/macrophages,” Clinical and Experimental
Allergy, vol. 37, no. 4, pp. 608–614, 2007.
[27] H. Uzui, S. K. Sinha, and T. B. Rajavashisth, “17𝛽-estradiol
inhibits oxidized low-density lipoprotein-induced increase in
matrix metalloproteinase-9 expression in human macropha-
ges,” Journal of Investigative Medicine, vol. 59, no. 7, pp. 1104–
1108, 2011.
[28] M. A. Rahat, B. Marom, H. Bitterman, L. Weiss-Cerem, A.
Kinarty, and N. Lahat, “Hypoxia reduces the output of matrix
metalloproteinase-9 (MMP-9) in monocytes by inhibiting its
secretion and elevating membranal association,” Journal of
Leukocyte Biology, vol. 79, no. 4, pp. 706–718, 2006.
Mediators of Inflammation 11
[29] N. Lahat, H. Bitterman, M. Engelmayer-Goren, D. Rosenzweig,
L.Weiss-Cerem, andM.A. Rahat, “Reduced TIMP-2 in hypoxia
enhances angiogenesis,” The American Journal of Physiology—
Cell Physiology, vol. 300, no. 3, pp. C557–C566, 2011.
[30] M. Cote, P. G. A. Rogueda, and P. C. Griffiths, “Effect of mole-
cular weight and end-group nature on the solubility of ethylene
oxide oligomers in 2H, 3H-decafluoropentane and its fully
fluorinated analogue, perfluoropentane,” Journal of Pharmacy
and Pharmacology, vol. 60, no. 5, pp. 593–599, 2008.
[31] J. G. Riess and M. P. Krafft, “Fluorocarbons and fluorosurfac-
tants for in vivo oxygen transport (blood substitutes), imaging,
and drug delivery,” Materials Research Society Bulletin, vol. 24,
no. 5, pp. 42–48, 1999.
[32] E. G. Schutt, D. H. Klein, R. M. Mattrey, and J. G. Riess,
“Injectablemicrobubbles as contrast agents for diagnostic ultra-
sound imaging: the key role of perfluorochemicals,” Ange-
wandte Chemie—International Edition, vol. 42, no. 28, pp. 3218–
3235, 2003.
[33] G. W. Bos, W. E. Hennink, L. A. Brouwer et al., “Tissue reac-
tions of in situ formed dextran hydrogels crosslinked by stere-
ocomplex formation after subcutaneous implantation in rats,”
Biomaterials, vol. 26, no. 18, pp. 3901–3909, 2005.
[34] C. J. De Groot, M. J. A. Van Luyn, W. N. E. Van Dijk-Wolthuis
et al., “In vitro biocompatibility of biodegradable dextran-based
hydrogels tested with human fibroblasts,” Biomaterials, vol. 22,
no. 11, pp. 1197–1203, 2001.
[35] S. Mo¨ller, J. Weisser, S. Bischoff, and M. Schnabelrauch, “Dex-
tran and hyaluronan methacrylate based hydrogels as matrices
for soft tissue reconstruction,”Biomolecular Engineering, vol. 24,
no. 5, pp. 496–504, 2007.
[36] A. Khadjavi, C. Magnetto, A. Panariti et al., “Chitosan-shelled
oxygen-loaded nanodroplets abrogate hypoxia dysregulation
of human keratinocyte gelatinases and inhibitors: new per-
spectives for chronic wound healing,” Toxicology and Applied
Pharmacology. In press.
[37] S. A. Eming, P. Martin, and M. Tomic-Canic, “Wound repair
and regeneration: mechanisms, signaling, and translation,”
Science TranslationalMedicine, vol. 6, no. 265, Article ID 265sr6,
2014.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
